transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.

Författare och institution:
Kathryn Rogers (-); Kevin M Felsenstein (-); Lori Hrdlicka (-); Zhiming Tu (-); Faris Albayya (-); Winnie Lee (-); Sarah Hopp (-); Mary-Jo Miller (-); Darcie Spaulding (-); Zhiyong Yang (-); Hilliary Hodgdon (-); Scott Nolan (-); Melody Wen (-); Don Costa (-); Jean-Francois Blain (-); Emily Freeman (-); Bart De Strooper (-); Veerle Vulsteke (-); Louise Scrocchi (-); Henrik Zetterberg (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Erik Portelius (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Birgit Hutter-Paier (-); Daniel Havas (-); Michael Ahlijanian (-); Dorothy Flood (-); Liza Leventhal (-); Gideon Shapiro (-); Holger Patzke (-); Richard Chesworth (-); Gerhard Koenig (-)
Publicerad i:
Molecular neurodegeneration, 7 s. 61
Artikel, refereegranskad vetenskaplig
Fulltextlänk (lokalt arkiv):
Sammanfattning (abstract):
Background: A hallmark of Alzheimer’s disease is the presence of senile plaques in human brain primarily containing the amyloid peptides Aβ42 and Aβ40. Many drug discovery efforts have focused on decreasing the production of Aβ42 through γ-secretase inhibition. However, identification of γ-secretase inhibitors has also uncovered mechanism-based side effects. One approach to circumvent these side effects has been modulation of γ-secretase to shift Aβ production to favor shorter, less amyloidogenic peptides than Aβ42, without affecting the overall cleavage efficiency of the enzyme. This approach, frequently called γ-secretase modulation, appears more promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer’s disease. Results: Here we describe EVP-0015962, a novel small molecule γ-secretase modulator. EVP-0015962 decreased Aβ42 in H4 cells (IC50 = 67 nM) and increased the shorter Aβ38 by 1.7 fold at the IC50 for lowering of Aβ42. AβTotal, as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed. EVP-0015962 did not cause the accumulation of other γ-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a γ-secretase inhibitor reduced processing of both. A single oral dose of EVP-0015962 (30 mg/kg) decreased Aβ42 and did not alter AβTotal peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt Aβ deposition was not present. In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food formulation) reduced Aβ aggregates, amyloid plaques, inflammatory markers, and cognitive deficits. Conclusions: EVP-0015962 is orally bioavailable, detected in brain, and a potent, selective γ-secretase modulator in vitro and in vivo. Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the production of Aβ42, attenuated memory deficits, and reduced Aβ plaque formation and inflammation in Tg2576 transgenic animals. In summary, these data suggest that γ-secretase modulation with EVP-0015962 represents a viable therapeutic alternative for disease modification in Alzheimer’s disease.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper
γ-secretase, Modulation, NSAID, Cognition, Amyloid, Alzheimer’s disease
Ytterligare information:
© 2012 Rogers et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Postens nummer:
Posten skapad:
2013-02-25 13:01
Posten ändrad:
2013-02-25 13:01

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007